PAVMED INC
PAVMNASDAQTrading Snapshot
- Day Range
- $2.08 – $2.24
- 52-Week Range
- $1.84 – $28.44
- Volume (shares)
- 10,749
- Avg Volume (shares)
- —
- Shares Outstanding
- 8.0M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $71,000
- Last Q Revenue
- $33,000
- P/E Ratio
- —
- P/S Ratio
- 160.6x
- EPS (TTM)
- $-9.80
- Dividend Yield
- —
- Dilution (1yr)
- +107.2%
PAVMED INC
PAVM
StockOtter · stockotter.spaceAbout PAVMED INC
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareholders strengthens L
Contrasting PAVmed (NASDAQ:PAVM) and InMode (NASDAQ:INMD)
PAVmed (NASDAQ: PAVM - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength o
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell col
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laborat
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW